Tilmann Lantzsch
Overview
Explore the profile of Tilmann Lantzsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Engel J, Wieder V, Bauer M, Kaufhold S, Stuckrath K, Wilke J, et al.
Breast Cancer Res Treat
. 2024 Nov;
209(1):209-210.
PMID: 39565513
No abstract available.
2.
Engel J, Wieder V, Bauer M, Kaufhold S, Stuckrath K, Wilke J, et al.
Breast Cancer Res Treat
. 2024 Aug;
209(1):27-38.
PMID: 39153127
Purpose: Systemic therapy plays a major part in the cure of patients with early breast cancer (eBC). However, personalized treatment concepts are required to avoid potentially harmful overtreatment. Biomarkers are...
3.
Schuler K, Bethmann D, Kaufhold S, Hartung C, Stuckrath K, Lantzsch T, et al.
Diagnostics (Basel)
. 2022 Oct;
12(10).
PMID: 36292215
Tumour-infiltrating lymphocytes (TILs) are considered to have prognostic and predictive value for patients with early breast cancer. We examined 1166 breast cancer patients from a prospective, multicentre cohort (Prognostic Assessment...
4.
Hartung C, Porsch M, Stuckrath K, Kaufhold S, Staege M, Hanf V, et al.
Breast Care (Basel)
. 2022 Jan;
16(6):637-647.
PMID: 35082572
Introduction: Triple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer (BC) with limited options for therapy. TNBC is a heterogeneous disease and tumors have been classified...
5.
Bauer M, Kantelhardt E, Stiewe T, Nist A, Mernberger M, Politt K, et al.
Oncotarget
. 2019 Apr;
10(20):1975-1992.
PMID: 30956778
Background: Genetic factors play a substantial role in breast cancer etiology. Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2...
6.
Bernhardt S, Bayerlova M, Vetter M, Wachter A, Mitra D, Hanf V, et al.
Breast Cancer Res
. 2017 Oct;
19(1):112.
PMID: 29020998
Background: Breast cancer tumors are known to be highly heterogeneous and differences in their metabolic phenotypes, especially at protein level, are less well-understood. Profiling of metabolism-related proteins harbors the potential...
7.
Berndt U, Leplow B, Schoenfeld R, Lantzsch T, Grosse R, Thomssen C
Breast Care (Basel)
. 2016 Oct;
11(4):240-246.
PMID: 27721710
Introduction: It is generally accepted that estrogens play a protective role in cognitive function. Therefore, it can be expected that subtotal estrogen deprivation following aromatase inhibition will alter cognitive performance....
8.
Lantzsch T, Lampe D, Kantelhardt E
Breast Care (Basel)
. 2014 Jan;
8(2):139-42.
PMID: 24419214
Background: Poland's syndrome, a rare congenital anomaly, consists of unilateral absence of the pectoralis major muscle, ipsilateral brachysyndactyly, and occasionally associated other malformations of the anterior chest wall, mamilla, and...
9.
Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, et al.
Breast Cancer Res Treat
. 2010 Jul;
123(2):437-45.
PMID: 20623180
In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such...
10.
Kluttig A, Trocchi P, Heinig A, Holzhausen H, Taege C, Hauptmann S, et al.
BMC Cancer
. 2007 Jun;
7:100.
PMID: 17570833
Background: The planned nationwide implementation of mammography screening 2007 in Germany will increase the occurrence of mammographically detected breast abnormalities. These abnormalities are normally evaluated by minimal invasive core biopsy....